Get startedLog in
    Picture of Lifecore Biomedical logo

    LFCR — Lifecore Biomedical Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Lifecore Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    R2022
    May 29th
    2023
    May 28th
    2024
    May 26th
    2025
    May 25th
    2025
    December 31st
    Period Length:52 W52 W52 W52 W7 M
    Source:10-K10-K10-K10-K10-KT
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue11110312812975.5
    Cost of Revenue
    Gross Profit39.12841.940.323.7
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Total Operating Expenses12314913714676.3
    Operating Profit-11.8-45.5-8.84-17.2-0.733
    Total Net Non Operating Interest Income / Expense
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-20.7-63.99.51-38.7-17.6
    Provision for Income Taxes
    Net Income After Taxes-15.5-64.29.33-38.7-18
    Net Income Before Extraordinary Items
    Extraordinary Items
    Net Income-117-99.612-38.7-18
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-117-99.612-44.4-20.1
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS1.55-1.220.606-1.18-0.539
    Dividends per Share